Rat Model of Candida Vaginal Infection

[1]  G. Santoni,et al.  Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats , 1997, Infection and immunity.

[2]  B. Hube.  Candida albicans secreted aspartyl proteinases. , 1996, Current topics in medical mycology.

[3]  J. Sobel,et al.  Immunopathogenesis of recurrent vulvovaginal candidiasis , 1996, Clinical microbiology reviews.

[4]  J. Sobel,et al.  Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections , 1995, Infection and immunity.

[5]  G. Santoni,et al.  Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection , 1995, Infection and immunity.

[6]  J. Sobel,et al.  Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis , 1995, Infection and immunity.

[7]  A. Cassone,et al.  Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis , 1995, Infection and immunity.

[8]  J. Sobel,et al.  Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis , 1994, Infection and immunity.

[9]  J. Sobel,et al.  Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis , 1993, Infection and immunity.

[10]  G. Carruba,et al.  Filamentous growth and elevated vaginopathic potential of a nongerminative variant of Candida albicans expressing low virulence in systemic infection , 1993, Infection and immunity.

[11]  F. Odds,et al.  Fungal morphology after treatment with itraconazole as a single oral dose in experimental vaginal candidosis in rats , 1991 .

[12]  A. Cassone,et al.  Vaginopathic and proteolytic Candida species in outpatients attending a gynaecology clinic. , 1991, Journal of clinical pathology.

[13]  J. Cutler,et al.  Putative virulence factors of Candida albicans. , 1991, Annual review of microbiology.

[14]  J. F. Ryley,et al.  Candida albicans--do mycelia matter? , 1990, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[15]  A. Cassone,et al.  The secreted aspartate proteinase of Candida albicans: physiology of secretion and virulence of a proteinase-deficient mutant. , 1990, Journal of general microbiology.

[16]  A. Cassone,et al.  Isolation, acid proteinase secretion, and experimental pathogenicity of Candida parapsilosis from outpatients with vaginitis , 1989, Journal of clinical microbiology.

[17]  J. Sobel.  Pathogenesis of Candida vulvovaginitis. , 1989, Current topics in medical mycology.

[18]  J. V. van Cutsem,et al.  Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. , 1987, Reviews of infectious diseases.

[19]  T. Savage,et al.  Ketoconazole in experimental vaginal candidosis in rats. , 1986, Antimicrobial Agents and Chemotherapy.

[20]  J. F. Ryley,et al.  Quantification of vaginal Candida albicans infections in rodents. , 1986, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[21]  I. Saji,et al.  Activity of SM-4470, a new imidazole derivative, against experimental fungal infections , 1986, Antimicrobial Agents and Chemotherapy.

[22]  O. Kinsman,et al.  Hormonal factors in vaginal candidiasis in rats , 1986, Infection and immunity.

[23]  J. Sobel.  Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. , 1985, American journal of obstetrics and gynecology.

[24]  J. Sobel,et al.  Experimental chronic vaginal candidosis in rats. , 1985, Sabouraudia.

[25]  J. Sobel,et al.  Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis , 1984, Antimicrobial Agents and Chemotherapy.

[26]  J. Sobel,et al.  Critical role of germ tube formation in the pathogenesis of candidal vaginitis , 1984, Infection and immunity.

[27]  J. F. Ryley,et al.  Azole resistance in Candida albicans. , 1984, Sabouraudia.

[28]  J. Sobel,et al.  Comparison of ketoconazole, Bay N7133, and Bay L9139 in the treatment of experimental vaginal candidiasis , 1983, Antimicrobial Agents and Chemotherapy.

[29]  J. F. Ryley,et al.  Experimental approaches to antifungal chemotherapy. , 1981, Advances in pharmacology and chemotherapy.

[30]  J. Sobel,et al.  Adherence of Candida albicans to human vaginal and buccal epithelial cells. , 1981, The Journal of infectious diseases.

[31]  J. V. van Cutsem,et al.  Ketoconazole in experimental candidosis. , 1980, Reviews of infectious diseases.

[32]  P. Erhard,et al.  Evaluation of vaginal antifungal formulations in vivo. , 1979, Postgraduate medical journal.

[33]  P. Kozinn,et al.  Experimental vaginal candidiasis in mice; its implications for superficial candidiasis in humans. , 1960, The Journal of investigative dermatology.